Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)GlobeNewsWire • 12/30/25
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA TreatmentSeeking Alpha • 12/10/25
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/10/25
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/09/25
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding AgreementGlobeNewsWire • 12/04/25
Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/22/25
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA DrugZacks Investment Research • 11/07/25
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 11/06/25
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three MonthsZacks Investment Research • 10/14/25
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)GlobeNewsWire • 10/13/25
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?Zacks Investment Research • 09/10/25
Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26Zacks Investment Research • 08/12/25
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business HighlightsGlobeNewsWire • 08/11/25